The vast majority of non-Hodgkin‘s lymphoma (NHL) are B-cell NHLs, the most common being diffuse large B-cell lymphoma (DLBCL). While most patients with DLBCL respond to initial therapy, over a third will develop refractory or relapsed (R/R) disease. Although there is no established standard of care, recent approvals of bispecific T-cell engagers, emerging therapies, and developing data are changing the treatment paradigm in R/R DLBCL. In this activity, Drs. Allison Rosenthal and Yasmin Karimi will review the latest conference data on current and emerging bispecific antibodies for R/R DLBCL.
Upon completion of this activity, participants should be better able to:
Assistant Professor, Medicine
University of Michigan
Ann Arbor, MI
Assistant Professor, Medicine
Medical Director, Adolescent and Young Adult Cancer Program
Mayo Clinic
Phoenix, AZ
Resources
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
